Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia
Open Access
- 13 March 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (6), 983-992
- https://doi.org/10.1182/bloodadvances.2019001126
Abstract
There is marked paucity of data regarding late effects in adolescents and young adults (AYAs) who undergo myeloablative conditioning (MAC) allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). We evaluated late effects and survival in 826 1-year disease-free survivors of MAC HCT for AYA AML, with an additional focus on comparing late effects based upon MAC type (total body irradiation [TBI] vs high-dose chemotherapy only). The estimated 10-year cumulative incidence of subsequent neoplasms was 4% (95% confidence interval [CI], 2%-6%); 10-year cumulative incidence of nonmalignant late effects included gonadal dysfunction (10%; 95% CI, 8%-13%), cataracts (10%; 95% CI, 7%-13%), avascular necrosis (8%; 95% CI, 5%-10%), diabetes mellitus (5%; 95% CI, 3%-7%), and hypothyroidism (3%; 95% CI, 2%-5%). Receipt of TBI was independently associated with a higher risk of cataracts only (hazard ratio [HR], 4.98; P < .0001) whereas chronic graft-versus-host disease (cGVHD) was associated with an increased risk of cataracts (HR, 3.22; P = .0006), avascular necrosis (HR, 2.49; P = .006), and diabetes mellitus (HR, 3.36; P = .03). Estimated 10-year overall survival and leukemia-free survival were 73% and 70%, respectively, and did not differ on the basis of conditioning type. In conclusion, late effects among survivors of MAC HCT for AYA AML are frequent and are more closely linked to cGVHD than type of conditioning.Keywords
This publication has 42 references indexed in Scilit:
- Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid LeukemiaTransplantation and Cellular Therapy, 2012
- Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell TransplantationJournal of Clinical Oncology, 2011
- Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioningBlood, 2011
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Solid cancers after allogeneic hematopoietic cell transplantationBlood, 2009
- Endocrine Complications after Hematopoietic Stem Cell Transplantation during Childhood and AdolescenceJournal of Korean Medical Science, 2009
- Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working PartyBlood, 2008
- Old and New Cancers after Hematopoietic-Cell TransplantationHematology, 2008
- Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantationBlood, 2007
- Patterns of gonadal dysfunction following bone marrow transplantationBone Marrow Transplantation, 1998